U.S. Food and Drug Administration Approves Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients

FDA News, New FDA Approvals
September 28, 2020
A+ A-
Email Print

Article Link: U.S. Food and Drug Administration Approves Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients

KING OF PRUSSIA, PA  – September 28, 2020 – CSL Behring, a global biotherapeutics leader, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Haegarda® (C1 Esterase Inhibitor…

Source: FDA New Drug Approvals

Posted by

Newer Post
Older Post